Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Renaissance of thalidomide].

F Waelput1, W Feremans, M Heenen

  • 1Institut de Pharmacie, U.L.B.

Revue Medicale De Bruxelles
|February 15, 2003
PubMed
Summary
This summary is machine-generated.

Thalidomide, once known for birth defects, is now reconsidered for its anti-angiogenic and immunomodulating effects. It shows promise in treating multiple myeloma and various skin conditions like erythema nodosum leprosis.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Septicaemia And Endocarditis Due to Streptococci of Lancefield Group.

Acta clinica Belgica·2016
Same author

Traitement Des Infections Bronchopulmonaires Aigues Par Le Laurylsulfate De Tetracycline Intra-Musculaire.

Acta clinica Belgica·2016
Same author

Epidermal kinetic alterations required to generate the psoriatic phenotype: a reappraisal.

Cell proliferation·2010
Same author

[Interest of immunohistochemic markers (Ki67, HMB45, p53) in risk analysis of congenital naevi of little and middle size].

Revue medicale de Bruxelles·2009
Same author

Time-kinetic study of repigmentation in vitiligo patients by tacrolimus or pimecrolimus.

Archives of dermatological research·2009
Same author

[Management of cutaneous toxicities induced by epidermal growth factor receptor inhibitors: a review].

Revue medicale de Bruxelles·2009

Area of Science:

  • Pharmacology
  • Immunology
  • Oncology

Context:

  • Thalidomide's historical teratogenicity is re-evaluated.
  • Emerging research highlights its therapeutic potential beyond initial concerns.

Purpose:

  • To explore the renewed applications of thalidomide.
  • To investigate its efficacy in treating multiple myeloma and inflammatory dermatoses.

Summary:

  • Thalidomide exhibits significant anti-angiogenic and immunomodulating properties.
  • These properties support its use in treating multiple myeloma.
  • It is also indicated for erythema nodosum leprosis, cutaneous lupus erythematosus, and severe aphthosis.

Impact:

  • Repurposing thalidomide offers new treatment avenues for challenging diseases.
  • Understanding its dual nature (teratogenic and therapeutic) is crucial for safe application.